Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurotoxicology ; 80: 105-111, 2020 09.
Article in English | MEDLINE | ID: mdl-32702364

ABSTRACT

The inhibitory glycine receptor (GlyR) is a key mediator of synaptic signalling in spinal cord, brain stem, and higher centres of the central nervous system. We examined the glycinergic activity of sarcophine (SN), a marine terpenoid known for its various biological activities, and its trans-diol derivative (7S, 8R)-dihydroxy-deepoxysarcophine (DSN). SN was isolated from the Red Sea soft coral Sacrophyton glaucum, DSN was semisynthesized by hydrolysis of the epoxide ring. In cytotoxicity tests against HEK293 cells, SN and DSN had LD50 values of 29.3 ± 3.0 mM and 123.5 ± 13.0 mM, respectively. Both compounds were tested against recombinant human α1 glycine receptors in HEK293 cells using whole-cell recording techniques. Both, SN and DSN were shown for the first time to be inhibitors of recombinant glycine receptors, with KIvalues of 2.1 ± 0.3 µM for SN, and 109 ± 9 µM for DSN. Receptor inhibition was also studied in vivo in a mouse model of strychnine toxicity. Surprisingly, in mouse experiments strychnine inhibition was not augmented by either terpenoid. While DSN had no significant effect on strychnine toxicity, SN even delayed strychnine effects. This could be accounted for by assuming that strychnine and sarcophine derivatives compete for the same binding site on the receptor, so the less toxic sarcophine can prevent strychnine from binding. The combination of modulatory activity and low level of toxicity makes sarcophines attractive structures for novel glycinergic drugs.


Subject(s)
4-Butyrolactone/analogs & derivatives , Anthozoa/metabolism , Brain/drug effects , Excitatory Amino Acid Antagonists/pharmacology , Receptors, Glycine/antagonists & inhibitors , Seizures/prevention & control , 4-Butyrolactone/chemical synthesis , 4-Butyrolactone/isolation & purification , 4-Butyrolactone/pharmacology , 4-Butyrolactone/toxicity , Animals , Binding Sites , Binding, Competitive , Brain/metabolism , Brain/physiopathology , Disease Models, Animal , Excitatory Amino Acid Antagonists/chemical synthesis , Excitatory Amino Acid Antagonists/isolation & purification , Excitatory Amino Acid Antagonists/toxicity , HEK293 Cells , Humans , Male , Mice , Protein Binding , Receptors, Glycine/genetics , Receptors, Glycine/metabolism , Seizures/chemically induced , Seizures/metabolism , Seizures/physiopathology , Strychnine
2.
Sci Pharm ; 84(3): 428-446, 2015 Sep 26.
Article in English | MEDLINE | ID: mdl-28117310

ABSTRACT

Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione ring. In this report, tadalafil analogues with an extended hydrophilic side chain on the piperazine nitrogen were designed to interact with particular hydrophilic residues in the binding pocket. This leads to analogues with moderate inhibitory activity on phosphodiesterase-5, even for isomers in which chiral carbons are of the S configuration.

SELECTION OF CITATIONS
SEARCH DETAIL